Trial record 11 of 31 for:
Open Studies | "Adrenal Insufficiency"
Physiological Response of Cortisol to Cardiac Catheterization
This study is currently recruiting participants.
Verified March 2013 by Creighton University
Information provided by (Responsible Party):
First received: March 28, 2013
Last updated: NA
Last verified: March 2013
History: No changes posted
Cortisol is essential for survival. The importance of cortisol response is most apparent in patients with partial or complete deficiency of glucocorticoids during stressful events such as illness or surgery.
||Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
||Physiological Response of Cortisol to Cardiac Catheterization
Primary Outcome Measures:
- cortisol change [ Time Frame: one month ] [ Designated as safety issue: No ]
On the day of the procedure a total of 4 venous blood samples for random plasma cortisol level will be obtained. Blood will be drawn at 5 minutes prior to the procedure, at 30 minutes and 60 minutes during the cardiac catheterization. Another sample will be drawn in 3 hours after cardiac catheterization prior to the patients discharge. a cortisol level will be drawn at a "nonstressful" visit
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||June 2014 (Final data collection date for primary outcome measure)
patients undergoing elective heart catheterization
It is known that cortisol and other stress hormones increase during acute myocardial infarction as well (9-11). Cardiac catheterization is an essential tool for the management of acute coronary syndrome, and for the evaluation of the burden of coronary artery disease in cardiac patients.
|Ages Eligible for Study:
||20 Years to 90 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
30 males and females, age 20-90 years who are scheduled for elective cardiac catheterization procedure.
- Patients undergoing elective cardiac catheterization, who are willing and able to give consent.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01822847
||Valentina Tarasova, MD
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 28, 2013
||March 28, 2013
||United States: Institutional Review Board
Keywords provided by Creighton University:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 05, 2013
Adrenal Gland Diseases
Endocrine System Diseases
Immune System Diseases
Hydrocortisone 17-butyrate 21-propionate